• Je něco špatně v tomto záznamu ?

Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis

R. Ciccocioppo, C. Mengoli, E. Betti, G. Comolli, I. Cassaniti, A. Piralla, P. Kruzliak, M. Caprnda, L. Pozzi, GR. Corazza, A. Di Sabatino, F. Baldanti

. 2021 ; 21 (3) : 379-388. [pub] 20210326

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012310

Grantová podpora
08064415 Fondazione IRCCS Policlinico San Matteo

Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are endowed with the ability of establishing lifelong latency in human hosts and reactivating in immunocompromised subjects, including patients suffering from ulcerative colitis (UC). We, therefore, aimed to investigate virus-specific immunity in UC patients. A cohort of 24 UC patients (14 responders and 10 refractory to therapy) and 26 control subjects was prospectively enrolled to undergo virus-specific serology (by ELISA assay) and assessment of both CD4+ and CD8+ virus-specific T-cell response (by interferon-γ enzyme-linked immunospotanalysis). In parallel, mucosal viral load was determined by quantitative real-time PCR and the values were correlated with both clinical and endoscopic indexes of activity. For statistics, the t-test, Mann-Withney test, Fisher's exact test and Spearman rank correlation test were applied; p < 0.05 was considered significant. EBV-specific CD4+ and CD8+ T-cell responses were significantly lower in UC patients compared to controls (p < 0.0001 and p = 0.0006, respectively), whereas no difference was found for HCMV-specific T-cell response. When dividing the UC group according to response to therapy, both responders and refractory UC patients showed a deficient EBV-specific CD4+ T-cell response with respect to controls (p < 0.04 and p = 0.0003, respectively). Moreover, both EBV and HCMV mucosal loads were significantly higher in refractory UC than in responders and controls (p = 0.007 and 0.003; and p = 0.02 and 0.001, respectively), and correlated with activity indexes. Steroid therapy seemed the main risk factor for triggering EBV colitis. Finally, no cases of IgM positivity were found in the study population. An impaired EBV-specific immunity was clearly evident in UC patients, mostly in those refractory to therapy. The ELISPOT assay may serve as new tool for quantifying and monitoring virus-specific T-cell immunity in UC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012310
003      
CZ-PrNML
005      
20220506130301.0
007      
ta
008      
220425s2021 it f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10238-021-00702-2 $2 doi
035    __
$a (PubMed)33772380
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Ciccocioppo, Rachele $u Gastroenterology Unit, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi, University of Verona, Piazzale L.A. Scuro, 10, 37134, Verona, Italy. rachele.ciccocioppo@univr.it
245    10
$a Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis / $c R. Ciccocioppo, C. Mengoli, E. Betti, G. Comolli, I. Cassaniti, A. Piralla, P. Kruzliak, M. Caprnda, L. Pozzi, GR. Corazza, A. Di Sabatino, F. Baldanti
520    9_
$a Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are endowed with the ability of establishing lifelong latency in human hosts and reactivating in immunocompromised subjects, including patients suffering from ulcerative colitis (UC). We, therefore, aimed to investigate virus-specific immunity in UC patients. A cohort of 24 UC patients (14 responders and 10 refractory to therapy) and 26 control subjects was prospectively enrolled to undergo virus-specific serology (by ELISA assay) and assessment of both CD4+ and CD8+ virus-specific T-cell response (by interferon-γ enzyme-linked immunospotanalysis). In parallel, mucosal viral load was determined by quantitative real-time PCR and the values were correlated with both clinical and endoscopic indexes of activity. For statistics, the t-test, Mann-Withney test, Fisher's exact test and Spearman rank correlation test were applied; p < 0.05 was considered significant. EBV-specific CD4+ and CD8+ T-cell responses were significantly lower in UC patients compared to controls (p < 0.0001 and p = 0.0006, respectively), whereas no difference was found for HCMV-specific T-cell response. When dividing the UC group according to response to therapy, both responders and refractory UC patients showed a deficient EBV-specific CD4+ T-cell response with respect to controls (p < 0.04 and p = 0.0003, respectively). Moreover, both EBV and HCMV mucosal loads were significantly higher in refractory UC than in responders and controls (p = 0.007 and 0.003; and p = 0.02 and 0.001, respectively), and correlated with activity indexes. Steroid therapy seemed the main risk factor for triggering EBV colitis. Finally, no cases of IgM positivity were found in the study population. An impaired EBV-specific immunity was clearly evident in UC patients, mostly in those refractory to therapy. The ELISPOT assay may serve as new tool for quantifying and monitoring virus-specific T-cell immunity in UC.
650    _2
$a CD4-pozitivní T-lymfocyty $x metabolismus $7 D015496
650    _2
$a CD8-pozitivní T-lymfocyty $x metabolismus $7 D018414
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ulcerózní kolitida $x farmakoterapie $x imunologie $x virologie $7 D003093
650    _2
$a Cytomegalovirus $x imunologie $x fyziologie $7 D003587
650    _2
$a cytomegalovirové infekce $x farmakoterapie $x imunologie $7 D003586
650    _2
$a DNA virů $x genetika $7 D004279
650    _2
$a infekce virem Epsteina-Barrové $x farmakoterapie $x imunologie $7 D020031
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a virus Epsteinův-Barrové $x imunologie $x fyziologie $7 D004854
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a steroidy $x škodlivé účinky $x terapeutické užití $7 D013256
650    _2
$a virová nálož $7 D019562
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mengoli, Caterina $u Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
700    1_
$a Betti, Elena $u Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
700    1_
$a Comolli, Giuditta $u Molecular Virology Unit, Microbiology and Virology Department, San Matteo Hospital Foundation, Pavia, Italy $u Experimental Research Laboratories, Biotechnology Area, San Matteo Hospital Foundation, Pavia, Italy
700    1_
$a Cassaniti, Irene $u Molecular Virology Unit, Microbiology and Virology Department, San Matteo Hospital Foundation, Pavia, Italy
700    1_
$a Piralla, Antonio $u Molecular Virology Unit, Microbiology and Virology Department, San Matteo Hospital Foundation, Pavia, Italy
700    1_
$a Kruzliak, Peter $u 2Nd Department of Surgery, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Pekarska 53, 65691, Brno, Czech Republic. kruzliakpeter@gmail.com $1 https://orcid.org/0000000270693784
700    1_
$a Caprnda, Martin $u First Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
700    1_
$a Pozzi, Lodovica $u Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
700    1_
$a Corazza, Gino Roberto $u Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
700    1_
$a Di Sabatino, Antonio $u Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
700    1_
$a Baldanti, Fausto $u Molecular Virology Unit, Microbiology and Virology Department, San Matteo Hospital Foundation, Pavia, Italy $u Department of Clinical, Surgical, Diagnostics and Pediatric Sciences, University of Pavia, Pavia, Italy
773    0_
$w MED00006222 $t Clinical and experimental medicine $x 1591-9528 $g Roč. 21, č. 3 (2021), s. 379-388
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33772380 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130253 $b ABA008
999    __
$a ok $b bmc $g 1789758 $s 1163511
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 3 $d 379-388 $e 20210326 $i 1591-9528 $m Clinical and Experimental Medicine $n Clin Exp Med $x MED00006222
GRA    __
$a 08064415 $p Fondazione IRCCS Policlinico San Matteo
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...